NCT00903708View on ClinicalTrials.gov

LY2275796 in Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Advanced Cancers
Interventions
DRUG

LY2275796

100 mg administered by vein as a loading dose daily over 3 days, and then as a maintenance dose weekly thereafter.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00903708 - LY2275796 in Advanced Cancer | Biotech Hunter | Biotech Hunter